Many brands of widely used medicines such as Telmisartan, Rabeprazole, Vitamin C, Furosemide are just not available.

With global giants Amazon and Netflix pouring money to develop original Indian content and desi players not far behind, the OTT race has entered an exciting phase.

Globally, the number of diabetes patients is at around half a billion with over 30 million in the US alone, the most sought after market for diabetes care companies, especially those into insulin.

Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.

The fund house believes that these are interesting times for Indian healthcare sector despite disappointing earnings in FY18. The sector has the potential to get re-rated after temporary disruptions get resolved

At the moment most experts are in a wait and watch mode, while some players from these sectors think that it could be a mixed bag.

Strides Pharma Science attributes its underwhelming performance to a confluence of headwinds and execution challenges.